: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group.
Toxicities and outcomes of 616 ibrutinib-treated patients in ... - PMC (616 KB)
: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression). : Patients in clinical trials were generally younger,